Comparing the MicroRNA Spectrum between Serum and Plasma by Wang, K. et al.
Comparing the MicroRNA Spectrum between Serum and
Plasma
Kai Wang1*, Yue Yuan1, Ji-Hoon Cho1, Sara McClarty1, David Baxter1, David J. Galas1,2
1 Institute for Systems Biology, Seattle, Washington, United States of America, 2 Luxembourg Center for Systems Biomedicine, University of Luxembourg, Luxembourg
City, Luxembourg
Abstract
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate various biological processes, primarily through interaction
with messenger RNAs. The levels of specific, circulating miRNAs in blood have been shown to associate with various
pathological conditions including cancers. These miRNAs have great potential as biomarkers for various pathophysiological
conditions. In this study we focused on different sample types’ effects on the spectrum of circulating miRNA in blood. Using
serum and corresponding plasma samples from the same individuals, we observed higher miRNA concentrations in serum
samples compared to the corresponding plasma samples. The difference between serum and plasma miRNA concentration
showed some associations with miRNA from platelets, which may indicate that the coagulation process may affect the
spectrum of extracellular miRNA in blood. Several miRNAs also showed platform dependent variations in measurements.
Our results suggest that there are a number of factors that might affect the measurement of circulating miRNA
concentration. Caution must be taken when comparing miRNA data generated from different sample types or
measurement platforms.
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Introduction
Measuring the levels of specific analytes in bodily fluids,
especially serum or plasma prepared from blood, is the most
commonly used method in diagnosis. It is relatively noninvasive
and in certain cases, with proper training and supervision, can be
self-administered by patients for disease management (e.g. a blood
sugar test). However, most of the current blood biomarkers are
inadequate in specificity and sensitivity for definitive disease
diagnosis. One of the major foci in biomedical research in the past
few decades has been to identify biomarkers, or panels of
biomarkers, in body fluids with clear disease association. Most of
these activities are centered on identifying protein-based bio-
markers; however, promise is still unfulfilled.
MicroRNAs (miRNAs) are endogenous 17 to 23 nucleotide-long
noncoding regulatory RNA molecules that modulate cellular
messenger RNA (mRNA) and protein levels by interacting with
specific mRNAs, usually at the 39 untranslated region (UTR),
through partial sequence complementation [1,2]. Thus far, over
1,000 human miRNAs have been identified (miRBase, www.
mirbase.org). Recently, a significant number of miRNAs have also
been found outside of the cells, and the levels of some of these
extracellular miRNAs in circulation have been linked to different
pathophysiological conditions. Examples of this include the
associations of miR-141 with prostate cancer, miR-499 with
myocardial infarction, and miR-122 with drug-induced liver injury
[3–7]. These findings raise the possibility of using the levels of
specific miRNAs in circulation as biomarkers for different
pathological conditions [8–12]. Compared to protein-based bio-
markers, miRNA offers several advantages: the complexity of
miRNA is much lower than that of proteins; the miRNAs are
stable in various bodily fluids; the sequences of many miRNAs are
conserved among different clinically relevant species; the expres-
sion of some miRNAs are restricted to specific tissues or biological
stages. The levels of miRNAs can also be easily measured by
various commonly used laboratory methods, including assorted
signal amplification strategies [8].
Despite significant progress in identifying the association of
specific circulating miRNAs in various diseases, factors that may
affect the measurement of circulating miRNA concentrations have
yet to be fully addressed. Previous reports on the exportation of
miRNAs from cells raised the prospect that plasma and serum
might exhibit some differences in their miRNA content. We
obtained serum and corresponding plasma samples from 12
healthy individuals to investigate the possible effects of different
types of blood sample preparation on miRNA measurement. Our
results suggested that different blood sample preparation methods
might affect the concentration measurement of individual circu-
lating miRNAs.
Results
Serum and plasma samples from 12 individuals, 6 males and 6
females, with ages ranging from 22 to 41, were used for our
measurements. Various blood cell components were also collected
from 6 (3 males and 3 females) of the 12 donors (Table 1). The
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general sample information and concentrations of isolated RNA
are listed on Table 1. No significant association between RNA
concentration with either the gender or the age of the donor was
observed. However the sera showed a higher RNA concentration
than the corresponding plasma samples (with a p value of 0.0312
calculated by two-sample t-test). WBC, RBC, and platelets had
much higher RNA concentrations than either plasma or serum, as
expected. Unlike the RNA from RBC or WBC, the pattern of
platelet total RNA is similar to serum and plasma on bioanalyzer
(Figure S1).
Plasma and Serum Contained Significant Number of
miRNAs
a) miRNA measured by Taqman card. The serum and
plasma miRNA spectrum from 6 normal individuals (3 males and
3 females) was profiled with Taqman miRNA panel (Table 1). The
number of detectable miRNA species from these samples ranged
from 137 (in ID-6 plasma) to 234 (in ID-1 plasma) (Table 1). 106
miRNAs could be seen in all plasma samples, 118 in all serum
samples, and 98 miRNAs could be seen in all plasma and serum
samples tested (Table S1). No significant correlation between the
number of detectable miRNA species with either the gender of the
donor, the type of sample used (serum or plasma), or the RNA
concentration was observed. Based on the 40-Ct values, there is no
statistically significant difference between serum and plasma’s
miRNA concentrations (p-value = 0.3991 from two-sample t-test)
(Table S1 and Figure 1A). However, the serum samples always
showed higher concentrations than plasma when we measured
specific miRNA levels with individual QPCR Taqman primers
regardless of the results from the initial Taqman card profiling,
examples are shown in Figure 2. Based on the Taqman card
measurement results, the most abundant miRNA species was miR-
223 for all the serum samples and one of the plasma samples tested
(Table S3).
The coefficient of variation (standard deviation/mean of
concentration) for individual miRNA across samples from different
donors was determined. Among the 6 plasma samples, miR-101
showed the highest concentration variation and miR-185 had the
most consistent concentration (Table 2). In sera, miR-576-3p and
miR-345 had the highest and lowest concentration variations,
respectively. Interestingly, the levels of MammU6, RNU44
(SNORD 44) and RNU48 (SNORD48) which had been used to
normalize miRNA concentration measurements were not consis-
tently detected in the serum and plasma samples tested. In
addition, the concentrations of these RNAs also showed significant
variations among samples (Table S1).
b) miRNA measured by Exiqon panels. With Exiqon
QPCR panels, the number of detectable miRNAs among different
samples ranged from 123 to 296, with an average of 181 in plasma
and 204 in serum. Among them, 90 miRNAs were shared in all
plasma samples, 99 in all serum samples, and 83 in both (Table 1
and Table S2). Similar to Taqman results, no significant
association between the numbers of detectable miRNA in relation
to either gender or RNA concentrations was observed. Serum has
more detectable miRNAs than plasma (Table 1). Most of the
miRNAs in serum showed higher concentrations than the
corresponding plasma samples (with a p-value = 0.0379 from
two-sample t-test) (Table S2 and Figure 1B). The higher
concentration of miRNAs in serum samples was also demonstrated
with individual QPCR primers on some of the miRNAs, examples
are shown in Figure 3. Except for one serum sample (sample 55-
29515), miR-451 was the most abundant miRNA species based on
the results of Exiqon miRNA QPCR panel (Table S3).
The coefficient of variation was used to determine the
concentration variation of miRNAs measured by Exiqon panels.
In plasma, miR-22 showed the highest concentration variation
while miR-92a had the most stable concentration across samples.
In serum, miR-29c and miR-720 had the highest and lowest
concentration variations, respectively (Table 2). Like the Taqman
miRNA measurement results, U6 and some SNORD RNAs were
not consistently detected in both serum and plasma samples tested
(Table S2).
The Results between Two QPCR Platforms Showed Low
Consistency
Samples from 4 individuals were profiled with both Taqman
and Exiqon miRNA QPCR panels. Based on the primer
annotations, 358 miRNAs were in common between Taqman
card A and Exiqon plate I and II. After combining the two
datasets, 67 miRNAs could be detected in all 4 serum and plasma
samples by both platforms. The average miRNA concentration of
the 67 commonly detectable miRNAs showed 6.7 Ct values higher
in Taqman than the Exiqon measurements. This was probably
caused by the pre-amplification step implemented in the Taqman
miRNA measurement protocol. Within each platform, both
Taqman and Exiqon exhibited high correlations between serum
and corresponding plasma samples (based on the 40-Ct values)
(Figure S2A). However, the 67 commonly detectable miRNAs in
both plasma and serum samples showed very low correlations
between the two platforms (Figure S2B).
When comparing the measurements between platforms, there
were several miRNAs that showed platform-associated amplifica-
tion; for example, miR-107 showed a much better amplification
with Exiqon compared to Taqman (Figure 4 and Tables S1 and
S2).
Blood Cells Components Contained a Significant Amount
of Detectable miRNAs
As expected, the blood cells had more detectable miRNA
species, ranging from 280 to 477, compared to their serum or
plasma counterparts (Tables 1 and Table S2). A significant
number of these miRNAs (206 of them) were shared among all
blood cell components. Either miR-223 or miR-451 was the most
abundant miRNA in all RBC, WBC and platelet samples (Table
S3). It is interesting to note that the concentration of miR-223 was
relatively low in RBC compared to WBC and platelets. As in
serum and plasma, U6 and SNORD RNAs were not detected in
all samples, especially in platelets (Table S2). The degree of
concentration variations of individual miRNAs in the WBC, RBC
and platelet samples from different donors was also examined,
and. the most variable and the most stable miRNA species were
listed, respectively in Table 3.
A Number of miRNAs are Presented in Specific Blood
Components
Of the 742 miRNAs in Exiqon panels, 178 were never detected
in any of the samples tested including serum, plasma and their
corresponding blood cell components. There were 206 miRNA
species that can be detected in all blood cell components (WBC,
RBC and Platelets) and 80 were in all samples tested (WBC, RBC,
Platelets, serum and plasma). Based on our criteria, there were 26
miRNAs can only be seen in RBC samples and 1 miRNA unique
to WBC (miR-24-5p) (Tables S2 and S4).
MicroRNA Spectrum in Human Serum and Plasma
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Discussion
There is a more than two-fold difference in the number of
detectable miRNA species between the lowest (123 detectable
miRNA in serum or plasma sample from 11-39691 with Exiqon
panel) and highest (296 detectable miRNA in serum sample from
ID-5 with Exiqon panel) number among serum and plasma
samples tested (Table 1). However, no correlation between the
number of detected miRNAs and the concentration of RNAs
obtained was observed (Table 1). Therefore, the common practice
of using similar amounts of RNAs might not be the best approach
for circulating miRNA measurements. The difference in the
number of detectable miRNA in the samples may have some
physiological implications. However, it is difficult to interpret the
significance of this difference without more detailed clinical
information about the normal donors.
For miRNA measurement, data normalization is still a chal-
lenge, especially for circulating miRNA. Several small RNA
species, such as U6 and SNORD RNAs have been used in
miRNA data normalization. However, they are either not
detectable or have very high concentration variations across
different samples in our study (Tables S1 and S2). This observation
suggests that RNAs like U6 or SNORD might not be suitable for
normalizing extracellular miRNA measurements.
The levels of tissue-specific miRNAs in circulation have been
advanced as potential blood biomarkers for various pathologies in
specific organs. For example, the liver-specific miR-122 in drug-
induced liver injury [12,13], the muscle-specific miR-133a and b in
muscle injury [13] and heart-specific miR-208 and miR-499 in
myocardial infarction [5,14]. Most of these miRNAs are not
routinely detectable in the normal serum or plasma samples used
in this study (Table S1). This supports the possibility of using the
levels of these organ-specific miRNAs in circulation as biomarkers
for site-specific pathologies.
RNA Including miRNAs May be Released from Blood Cells
into Serum During Coagulation Process
Since the serum and plasma were collected at the same time
from the same individual, the higher RNA concentration in serum
(in 10 out of 12 samples) (Table 1) suggests that additional RNA
was released from cells during the coagulation process. Cell lysis,
especially the highly abundant red blood cells, during the
coagulation process is one of the plausible explanations for this
RNA concentration difference between serum and plasma.
However, the concentrations of some of the highly abundant
miRNA species in blood cell components such as, miR-150 in
WBCs, miR-16 in RBCs and miR-126 in platelets were almost the
same between serum and plasma (Table S2). In addition, the
miRNA concentration difference between serum and plasma
showed some associations with miRNA spectrum in platelets and
WBCs, instead of the most abundant cell population, RBCs, in the
blood (Figure S3).
This RNA concentration difference between serum and plasma
is consistent with the idea of RNA/miRNA ‘trafficking’’ between
cellular compartments and the extracellular environment [7,15–
21]. During the coagulation process, blood cells are exposed to
a ‘‘stressful environment’’ which may ‘‘stimulate’’ the release of
certain miRNAs and other RNAs, as was observed when cells were
exposed in vitro to serum-free conditions [7]. In addition, the
platelets also contained significant amounts of RNA (Table 1) [22]
which might also be released into the serum during the
coagulation process.
The difference of molecular composition between serum and
plasma is well documented [23–27]. For example, the coagulation
process increases sample-to-sample variations on the observed
proteome which makes data analysis and comparison difficult.
Our miRNA study yields a similar conclusion and suggests that
plasma may be the sample of choice in studying circulating
miRNA, since RNA released during the coagulation process may
change the true repertoire of circulating miRNA. When using
archived samples in circulating miRNA studies, special attention
Figure 1. Comparing the individual miRNA concentrations between serum and plasma. The average concentrations (40-Ct values) of
detected miRNAs in all serum and plasma samples within each platform were plotted – each point represents the average from all individuals of
a specific miRNA. The Y-axis represents the average miRNA concentrations in serum and X-axis is the average concentration of corresponding plasma.
The results from Taqman are showed in panel A and Exiqon are showed in panel B.
doi:10.1371/journal.pone.0041561.g001
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must be given to this difference, since the majority of the archived
samples are stored as serum.
The Concentration for Some miRNAs may be Affected by
Gender and the Measurement Platform
Gender-associated molecular differences have been reported in
serum and platelet proteomes recently [28–30]. In addition to the
concentration differences of some miRNAs between serum and
plasma, a number of miRNAs showed concentration differences
between genders. For example, miR-130b and miR-18b have
slightly higher concentrations in male serum samples measured by
Taqman platform (Table S1). This gender-associated circulating
miRNA concentration difference has also been observed recently
[31]. Even though the biological implications of these differences
are yet to be determined, we cannot exclude the possibility that
they are involved in some gender-associated functions.
The poor agreement among different miRNA measurement
platforms has been reported earlier [32,33]. The observation of
low measurement consistency between the two commonly used
QPCR miRNA measurement platforms and miRNA concentra-
tion differences between serum and plasma further illustrate the
need for a commonly accepted miRNA measurement platform
and sample preparation method, so that cross-study comparisons
and independent data validations can be performed more
effectively.
While there are numerous encouraging reports on the use of
specific circulating miRNAs as biomarkers for various pathological
conditions, it is important to understand factors that might affect
the measurement of extracellular miRNA concentration and take
these explicitly into account in diagnostic protocols. Our results
suggest that circulating miRNA levels may be affected by various
intrinsic and extrinsic factors including: the gender of the donor,
the measurement platform used, and type of samples obtained.
Even though some of these intrinsic factors may be associated with
specific biological activities; however, with limited samples used in
the study, it is not our intention to further interpret the results for
its biological implications. Our findings simply illustrate the need
for a larger and more comprehensive study with additional serum
and plasma samples from better controlled donors in order to
Figure 2. Examples of miRNA concentration differences between serum and plasma using individual Taqman QPCR primers. The
sample IDs were listed on the X-axis and the miRNA concentrations were displayed on the Y-axis (in 40-Ct value). The miRNA IDs were indicated on
top of the graph. Open bars represent plasma samples and the solid bars represent the corresponding serum samples. The values of standard
derivation were obtained from three independent measurements. The original measurement results from Taqman card showed higher 40-Ct values
since a pre-amplification step was employed. Two-way ANOVA was used to determine the statistical significance of the miRNA concentration
differences between serum and plasma (p-values are shown in the figure).
doi:10.1371/journal.pone.0041561.g002
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establish the boundaries for the use of circulating miRNA-based
biomarkers. In addition, the standardization for sample prepara-
tion and miRNA measurement method is urgently needed to
further develop circulating miRNA based biomarker.
Materials and Methods
Sample and RNA Isolation
Samples were obtained from either Biological Specialty
Corporation (Biological Specialty Corporation, Colmar, PA) or
Innovative Research (Innovative Research, Novi, MI). All samples
were collected from healthy individuals with proper approvals by
institutional review boards. The serum, plasma, and blood cell
fractions were prepared according to standard protocols. In brief,
serum was prepared by leaving the blood at room temperature for
one hour before harvesting the supernatant. Plasma, RBC, WBC
and platelets were prepared from 30 mLs of EDTA blood. The
blood was initially centrifuged at 10006 g for 15 minutes to
separate the plasma and blood cells. The supernatant was carefully
removed and centrifuged again at 25006 g for 15 minutes to
separate plasma and platelets. The platelet pellet was then
resuspended in 7 ml of phosphate buffered saline (PBS, 137 mM
NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4,
pH 7.5). The buffy coat from the initial spin was carefully collected
and resuspended in RBC lysis buffer (10 mM KHCO3, 150 mM
NH4Cl and 0.1 mM EDTA pH8.0) to remove RBC. The WBC
Table 2. The list of miRNAs with the most and least concentration variations in serum and plasma samples and measurement
platforms.
Platform Taqman Exiqon
Sample Plasma Serum Plasma Serum
Variability miRNA ID# Variability* miRNA ID# Variability* miRNA ID# Variability* miRNA ID# Variability*
High miR-101 0.3095 miR-576-3p 0.3164 miR-22 0.2216 miR-29c 0.2424
miR-376c 0.3002 miR-532-5p 0.2904 miR-199a-3p 0.2048 miR-106b 0.2400
miR-155 0.2965 miR-18b 0.2723 miR-199a-5p 0.1939 miR-424 0.2115
miR-532-5p 0.2732 miR-10a 0.2419 miR-328 0.1920 miR-148a 0.2093
miR-302c 0.2445 miR-302c 0.2364 miR-29c 0.1897 miR-199a-3p 0.2074
Low miR-18a 0.0492 miR-324-3p 0.0307 miR-346 0.0837 miR-1979 0.0806
miR-320a 0.0468 miR-126 0.0297 miR-486-5p 0.0826 miR-92a 0.0780
miR-106b 0.0400 miR-320a 0.0295 miR-16 0.0820 miR-1974 0.0712
miR-345 0.0364 miR-19b 0.0282 miR-720 0.0738 miR-934 0.0584
miR-185 0.0304 miR-345 0.0270 miR-92a 0.0644 miR-720 0.0563
*Coefficient of variation (standard deviation/mean) was used to measure the variability.
#Common miRNA species between serum and plasma were listed in boldface characters.
doi:10.1371/journal.pone.0041561.t002
Figure 3. Examples of miRNA concentration differences between serum and plasma using individual Exiqon QPCR primers. The
sample IDs were listed on the X-axis and the miRNA concentrations were displayed on the Y-axis (in 40-Ct value). The miRNA IDs were indicated on
top of the graph. Open bars represent plasma samples and the solid bars represent the corresponding serum samples. The values of standard
derivation were obtained from three independent measurements. Two-way ANOVA was used to determine the statistical significance of the miRNA
concentration differences between serum and plasma (p-values are shown in the figure).
doi:10.1371/journal.pone.0041561.g003
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containing solution was then spun at 10006 g for 10 minutes to
collect WBC. The cell pellet was resuspended in 7 mL of PBS.
The RBC fraction was taken directly from the original cell pellet.
For serum or plasma, total RNA was extracted from 100 ml of the
sample using the miRNeasy kit (Qiagen, Valencia, CA) as
previously described [6,12]. For RBC, WBC and platelets, 50 ml
Figure 4. Certain miRNAs showing different measurement efficiency between measurement platforms. The sample IDs and type of
samples were listed on the X-axis. The miRNA concentrations were displayed on the Y-axis (in 40-Ct value). Gray bars represent Exiqon measurement
results while solid bars represent the Taqman measurements from the same sample. The values of standard derivation were obtained from three
independent measurements.
doi:10.1371/journal.pone.0041561.g004
Table 3. The list of miRNAs with the most and least concentration variations in different blood cell samples and measurement
platforms.
Platform Exiqon
Sample WBC RBC Platelets
Variability miRNA ID Variability* miRNA ID Variability* miRNA ID Variability*
High miR-33a 0.2246 miR-520b 0.2578 miR-379* 0.2494
miR-136 0.2245 miR-33a 0.2515 miR-379 0.2300
miR-101* 0.2053 miR-517c 0.2184 miR-369-5p 0.2232
miR-543 0.1964 miR-338-3p 0.2169 miR-190 0.2227
miR-96 0.1846 miR-100 0.2150 miR-654-3p 0.2218
Low miR-30e 0.0172 miR-26a 0.0076 miR-423-5p 0.0368
miR-27b 0.0161 miR-15b 0.0070 miR-130a 0.0363
miR-23a 0.0152 miR-92a 0.0066 miR-210 0.0329
miR-93* 0.0151 miR-19b 0.0066 miR-720 0.0284
miR-548c-5p 0.0135 miR-30b 0.0063 miR-1974 0.0164
*Coefficient of variation (standard deviation/mean) was used to measure the variability.
#Common miRNA species between serum and plasma were listed in boldface characters.
doi:10.1371/journal.pone.0041561.t003
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of the resuspended cell pellets were used in RNA extraction. The
extracted RNA was assessed for quality and quantity with Agilent
2100 Bioanalyzer (Agilent, Santa Clara, CA) and NanoDrop 1000
spectrophotometer (Thermo Scientific, Wilmington, DE).
MicroRNA Measurement
For the Taqman assay (Applied Biosystems, Carlsbad, CA),
12 ml of isolated RNA was dried and resuspended in 3 ml of water.
The cDNA was then generated using Megaplex RT Primer pools.
Pre-amplification was performed using 2.5 ml cDNA according to
the manufacturer’s protocol. The resulting samples were diluted
and loaded onto the TaqManH Array Human miRNA Panel. For
Exiqon (Exiqon, Woburn, MA) miRNA profiling, 20 ml of RNA
was used for cDNA synthesis using MiRCURY LNATM Universal
RT kit. The cDNA was then diluted and dispensed into the
Exiqon Human miRNA panels. Since it is difficult to obtain
accurate RNA concentrations we used the same volume of RNA
isolated from serum and plasma samples in miRNA measure-
ments. We only used card A in Taqman-based miRNA
measurements, since it contained the majority of abundant
miRNA species. The blood cell fractions were profiled with
Exiqon miRNA panels only. QPCR was conducted with
a 7900HT fast real-time PCR system (Applied Biosystems, Foster
City, CA). Amplification results were analyzed with SDS 2.3
(Applied Biosystems, Foster City, CA). The amplification curves
were individually inspected and miRNAs with abnormal ampli-
fication patterns or Ct values greater than 35 were removed from
analysis. The complete Taqman and Exiqon QPCR miRNA
profiling results are provided in Tables S1 and S2.
Supporting Information
Figure S1 The Bioanalyzer electropherogram converted
gel like image of RNA isolated from different sample
types. The sample types are indicated on the top and the position
of 18S and 28S RNAs are labeled by arrows.
(TIF)
Figure S2 Comparing the similarity of miRNA spec-
trum between serum and plasma. Scatter plots were used to
demonstrate the similarity of miRNA concentrations between
serum and plasma within the same measurement platform (A).
The platform was indicated on top of the figure. Different
platforms gave low correlation on concentration measurement (B)
within either serum or plasma samples. The sample type was
labeled on top of the figure. The plots were based on the average
concentrations of 67 commonly detectable miRNA species in both
Taqman and Exiqon QPCR platforms
(TIF)
Figure S3 The miRNA concentration between serum
and plasma showed some association with miRNA
concentrations in platelets and WBC. Scatter plots were
used to demonstrate the correlation of miRNA concentration
difference between serum and plasma and difference between
platelets and plasma (A), WBC and plasma (B), and RBC and
plasma (C). The average miRNA concentration differences
between serum and plasma were represented on the Y-axis while
the average differences between blood cell components and
plasma were on X-axis. The plots were based on the average
concentrations of 67commonly detectable miRNAs in all the
samples.
(TIF)
Table S1 The serum and plasma miRNA measured by
Taqman cards.
(XLS)
Table S2 The serum and plasma miRNA measured by
Exiqon miRNA panels.
(XLS)
Table S3 The list of top 5 most abundatn miRNAs in
different samples.
(XLS)
Table S4 The list of miRNAs showing preferential
expression pattern among different blood components.
(XLS)
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